The Autoimmune Disease Diagnostics Market is projected to reach $7.53 billion by 2029, at a CAGR of 6.5% from 2022–2029. Autoimmune disease testing involves testing for antibodies that attack the body’s healthy cells and tissues. Autoimmune disease testing can be done using various tests, including antinuclear antibodies (ANA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, immunoglobulins, and routine blood tests. These tests are used to test for systemic autoimmune diseases affecting multiple organs or systems or specific autoimmune diseases.
The growth of this market is attributed to the increasing prevalence of autoimmune diseases and advances in the early diagnosis of autoimmune diseases. In addition, increasing investments and funding for research related to autoimmune diseases and untapped opportunities in developing countries are expected to provide significant growth opportunities for this market.
However, difficulty in diagnosing an autoimmune disease is restraining the growth of this market to a notable extent. In addition, an unfavorable reimbursement scenario is a major challenge for the growth of this market.
The Impact of COVID-19 on the Autoimmune Disease Diagnostics market
The outbreak of COVID-19 was a public health crisis and led to nationwide lockdowns and restrictions in many countries. A majority of the health services & resources were diverted to prioritizing COVID-19. Similarly, the laboratory resources and personnel were directed toward fighting the COVID-19 pandemic. The hospitals also saw a large influx of COVID-19 patients engaging their resources in testing and treatment of the patients infected with the virus. As a result, many non-essential, non-urgent, or elective procedures and appointments were canceled, delayed, or postponed, including the diagnostic testing of autoimmune diseases, which negatively impacted the adoption of tests.
The stringent lockdowns and restrictions led to supply chain disruption leading to delays in delivering the laboratory reagents and equipment. These factors negatively impacted the growth of the market to a certain extent; however, the market is gaining traction as diagnostic testing services are recovering.
However, several studies revealed that COVID-19 worsens the condition in people with autoimmune diseases, which is likely to boost the demand for autoimmune disease diagnostics, thereby positively impacting the market.
Click here to: Get Free Sample Copy of this report
Increased Awareness Regarding the Autoimmune Diseases to Drive Market Growth
Stress, genetic mutations, unhealthy eating habits, and environmental factors are among the leading causes of autoimmune diseases. The high prevalence of autoimmune diseases globally boosts the demand for autoimmune disease diagnostics. For instance, according to the CDC National Diabetes Statistics Report, 2020, around 1.4 million people in the U.S. suffer from Type-1 diabetes. This number is estimated to increase to 2.1 million by 2040. Moreover, there has been an increase in awareness regarding the diagnosis and treatment of autoimmune diseases among people, which is attributed to the initiatives taken by several public and private organizations. For instance, every year in March, the Autoimmune Association (U.S.) carries out events and campaigns for the entire month to raise awareness, spread information, and increase knowledge about autoimmune disorders.
The early diagnosis of autoimmune diseases and disorders proves crucial in reducing disability, morbidity and mortality among people, thereby driving the growth of the autoimmune disease diagnostics market.
Developing Countries to Offer Growth Opportunities for the Market
Developed countries have a higher market penetration rate compared to developing countries due to the high diagnosis rate. According to the hygiene hypothesis, children in developed countries who are not exposed to robust microbial challenges as compared to children from developing countries have altered immune homeostasis and an increased risk for several immune-mediated diseases. The hygiene hypothesis is based upon epidemiological data, particularly migration studies, showing that subjects migrating from low-incidence to high-incidence countries acquire immune disorders.
The adoption of unhealthy lifestyles has increased in developing countries due to increasing urbanization, fast food consumption, less physical activity, stress, and other factors. These factors are responsible for increasing the incidences of autoimmune disease in developing countries.
Key Findings of the Autoimmune Disease Diagnostics Market Study:
Based on Product, in 2022, the Reagents, Assays, and Kits Segment is Expected to Dominate to Market
Based on product, the Autoimmune Disease Diagnostics market is segmented into reagents, assays, & kits and instruments. In 2022, the reagents, assays, and kits segment is expected to account for the largest share of the autoimmune disease diagnostics market. The large market share of this segment is attributed to factors such as the high diagnosis rate of autoimmune diseases in developed countries, coupled with the recurring purchase of reagents and kits.
Based on Test Type, in 2022, the Antinuclear Antibodies (ANA) Segment is Expected to Dominate the Market
Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibodies (ANA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, immunoglobulins, routine blood tests, immunohistochemistry (IHC), flow cytometry, and other test types. In 2022, the antinuclear antibodies (ANA) segment is expected to account for the largest share of the autoimmune disease diagnostics market. Antinuclear antibodies tests look for autoantibodies in blood, which attack one’s healthy cells. Antibodies are formed in the blood much earlier than the onset of the actual disease in an individual. This enables the early diagnosis of the disease, which helps to reduce morbidity and mortality due to the disease. Thus, the high prevalence of autoimmune disease and the need for early diagnosis of autoimmune disease are the factors responsible for the large market share of this segment.
Based on Disease Type, in 2022, the Systemic Autoimmune Diseases Segment is Expected to Dominate the Market
Based on disease type, the autoimmune disease diagnostics market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. In 2022, the systemic autoimmune diseases segment is expected to account for the largest share of the autoimmune disease diagnostics market. Systemic autoimmune diseases affect multiple organs or systems, unlike localized autoimmune diseases, which only affect a certain organ or a region of the body. Some of the most commonly occurring autoimmune diseases are systemic in nature, including rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus (SLE). For instance, according to the World Health Organization, as of 2021, around 14 million people had rheumatoid arthritis globally. Thus, the high prevalence of systemic autoimmune diseases is one of the key factors for the large share of the segment.
Based on End User, in 2022, the Hospitals & Clinics Segment is Expected to Dominate the Market
Based on end user, the autoimmune disease diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, and academic & research institutes. In 2022, the hospitals & clinics segment is expected to account for the largest share of the autoimmune disease diagnostics market. The large market share of this segment is attributed to factors such as expanding diagnostics capabilities across the hospitals and high patient preference for hospitals as hospitals offer complete care, including diagnosis, treatment, surgeries, and physiotherapy.
Asia-Pacific: The Fastest-Growing Market
Asia-Pacific is slated to register the highest growth rate in the autoimmune disease diagnostics market during the forecast period. The high market growth in Asia-Pacific is attributed to the advancing healthcare infrastructure in the region, increasing patient pool, rising healthcare expenditure, and increasing awareness and diagnostic capabilities of autoimmune diseases.
Key Players
The report includes a competitive landscape based on an extensive assessment of product portfolio, test type, disease type, end user, geographic presence, and the key growth strategies adopted by leading market players in the industry over the past years. The key players profiled in the Autoimmune Disease Diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Myriad Genetics, Inc. (U.S.), EUROIMMUN Medizinische Labordiagnostika AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).
Scope of the Report:
Autoimmune Disease Diagnostics Market, by Product Type
Autoimmune Disease Diagnostics market, by Test Type
Autoimmune Disease Diagnostics market, by Disease Type
Autoimmune Disease Diagnostics market, by End User
Autoimmune Disease Diagnostics market, by Geography
Key questions answered in the report:
The autoimmune disease diagnostics market report covers the market sizes & forecasts based on product, test type, disease type, end user, and geography. This report involves the value analysis of various segments and subsegments of the autoimmune disease diagnostics market at the regional and country levels.
The autoimmune disease diagnostics market is projected to reach $7.53 billion by 2029, at a CAGR of 6.5% during the forecast period of 2022–2029.
Based on the product, the autoimmune disease diagnostics market is segmented into reagents, assays, and kits and instruments. In 2022, the reagents, assays, and kits segment is expected to account for the largest share of the autoimmune disease diagnostics market due to the recurring demand for assays & reagents and the high prevalence of autoimmune diseases in developed countries.
Based on test type, the autoimmune disease diagnostics market is segmented into antinuclear antibodies (ANA), C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), rheumatoid factor, immunoglobulins, routine blood tests, and other test types. In 2022, the antinuclear antibody (ANA) segment is expected to account for the largest share of the autoimmune disease diagnostics market due to the high prevalence of autoimmune diseases and the benefits offered by the ANA test of early autoimmune disease diagnosis.
Based on disease type, the autoimmune disease diagnostics market is segmented into systemic autoimmune diseases and organ-specific autoimmune diseases. In 2022, the systemic autoimmune diseases segment is expected to account for the largest share of the autoimmune disease diagnostics market.
Based on end user, the autoimmune disease diagnostics market is segmented into hospitals & clinics, diagnostic laboratories, and academic & research institutes. In 2022, the hospitals & clinics segment is estimated to account for the largest share of the Autoimmune Disease Diagnostics market.
The growth of this market is attributed to factors such increasing prevalence of autoimmune diseases and advances in the early diagnosis of autoimmune diseases. In addition, increasing investments and funding for research related to autoimmune diseases and untapped opportunities in developing countries are expected to provide significant growth opportunities for this market.
Difficulty in diagnosing an autoimmune disease is restraining the growth of this market. Furthermore, an unfavorable reimbursement scenario is a major challenge for the growth of this market
The key players operating in the Autoimmune Disease Diagnostics market are Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Beckman Coulter, Inc. (U.S.), Abbott Laboratories (U.S.), Myriad Genetics, Inc. (U.S.), EUROIMMUN Medizinische Labordiagnostika AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Siemens Healthineers AG (Germany), Grifols, S.A. (Spain), and Creative Diagnostics (U.S.).
The Asia-Pacific region is slated to register the highest growth rate during the forecast period and offer significant growth opportunities for the players operating in this market. The fast market growth in Asia-Pacific is attributed to factors such as advancing healthcare infrastructure in the region, increasing patient pool, rising healthcare expenditure, and increasing prevalence of autoimmune diseases.
This report provides pre & post COVID-19 market estimates.
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Process
2.2. Data Collection & Validation
2.2.1. Secondary Research
2.2.2. Primary Research
2.3. Market Assessment
2.3.1. Market Size Estimation
2.3.1.1. Bottom-up Approach
2.3.1.2. Top-down Approach
2.3.1.3. Growth Forecast
2.3.2. Market Share Analysis
2.4. Assumptions for the Study
2.5. Limitations for the Study
3. Executive Summary
4. Market Insights
4.1. Market Overview
4.2. Drivers
4.2.1. Increasing Prevalence of Autoimmune Disorders
4.2.2. Advances in the Early Diagnosis of Autoimmune Diseases
4.3. Restraints
4.3.1. Difficulty in Diagnosing Autoimmune Diseases
4.4. Opportunities
4.4.1. Increasing Investments & Funding for Autoimmune Diseases
4.4.2. Developing Countries
4.5. Challenges
4.5.1. Unfavourable Reimbursement Scenarios
4.6. The Impact of COVID-19 on the Autoimmune Disease Diagnostics Market
5. Autoimmune Disease Diagnostics Market, by Product Type
5.1. Introduction
5.2. Reagents, Kits, and Assays
5.3. Instruments
6. Autoimmune Disease Diagnostics Market, by Test Type
6.1. Introduction
6.2. Antinuclear Antibodies (ANA) Test
6.3. C-reactive Protein (CRP) Test
6.4. Erythrocyte Sedimentation Rate (ESR) Test
6.5. Rheumatoid Factor Test
6.6. Immunoglobulins Test
6.7. Routine Blood Tests
6.8. Other Test Types
7. Autoimmune Disease Diagnostics Market, by Disease Type
7.1. Introduction
7.2. Systemic Autoimmune Diseases
7.3. Organ-specific Autoimmune Diseases
8. Autoimmune Disease Diagnostics Market, by End User
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Diagnostic Laboratories
8.4. Academic & Research Institutes
9. Autoimmune Disease Diagnostics Market, by Geography
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.3. Europe
9.3.1. Germany
9.3.2. France
9.3.3. U.K.
9.3.4. Italy
9.3.5. Spain
9.3.6. Rest of Europe (RoE)
9.4. Asia-Pacific
9.4.1. Japan
9.4.2. China
9.4.3. India
9.4.4. Rest of Asia-Pacific (RoAPAC)
9.5. Latin America
9.5.1. Brazil
9.5.2. Mexico
9.5.3. Rest of Latin America (RoLATAM)
9.6. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Key Growth Strategies
10.3. Competitive Benchmarking
10.4. Market Share Analysis (2021)
11. Company Profiles (Business Overview, Financial Overview, Product Portfolio, and Strategic Developments)
11.1. Thermo Fisher Scientific Inc.
11.2. Bio-Rad Laboratories, Inc
11.3. Beckman Coulter, Inc.
11.4. Abbott Laboratories
11.5. EUROIMMUN Medizinische Labordiagnostika AG
11.6. F. Hoffmann-La Roche AG
11.7. Siemens Healthineers AG
11.8. Grifols, S.A.
11.9. Creative Diagnostics
11.10. Myriad Genetics, Inc.
12. Appendix
12.1. Questionnaire
12.2. Available Customization
List of Tables
Table 1 Autoimmune Disease Diagnostics Market Drivers: Impact Analysis (2022–2029)
Table 2 Autoimmune Disease Diagnostics Market Restraints: Impact Analysis (2022–2029)
Table 3 Autoimmune Disease Diagnostics Market Size, by Product Category, 2020–2029 (USD Million)
Table 4 Global Autoimmune Disease Diagnostic Reagents, Kits, and Assays Market Size, by Country/Region, 2020–2029 (USD Million)
Table 5 Global Autoimmune Disease Diagnostic Instruments Market Size, by Country/Region, 2022–2029 (USD Million)
Table 6 Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 7 Autoimmune Disease Diagnostics Market Size for Antinuclear Antibody (ANA) Test, by Country/Region, 2020–2029 (USD Million)
Table 8 Autoimmune Disease Diagnostics Market Size for C-reactive Protein (CRP) Test, by Country/Region, 2020–2029 (USD Million)
Table 9 Autoimmune Disease Diagnostics Market Size for Erythrocyte Sedimentation Rate (ESR) Test, by Country/Region, 2022–2029 (USD Million)
Table 10 Autoimmune Disease Diagnostics Market Size for Rheumatoid Factor Test, by Country/Region, 2020–2029 (USD Million)
Table 11 Autoimmune Disease Diagnostics Market Size for Immunoglobulins Test, by Country/Region, 2020–2029 (USD Million)
Table 12 Autoimmune Disease Diagnostics Market Size for Routine Blood Tests, by Country/Region, 2020–2029 (USD Million)
Table 13 Autoimmune Disease Diagnostics Market Size for Other Test Types, by Country/Region, 2022–2029 (USD Million)
Table 14 Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 15 Autoimmune Disease Diagnostics Market Size for Systemic Diseases, by Country/Region, 2022–2029 (USD Million)
Table 16 Autoimmune Disease Diagnostics Market Size for Organ-specific Diseases, by Country/Region, 2022–2029 (USD Million)
Table 17 Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 18 Autoimmune Disease Diagnostics Market Size for Hospitals & Clinics, by Country/Region, 2020–2029 (USD Million)
Table 19 Autoimmune Disease Diagnostics Market Size for Diagnostic Laboratories, by Country/Region, 2022–2029 (USD Million)
Table 20 Autoimmune Disease Diagnostics Market Size for Academic & Research Institutes, by Country/Region, 2020–2029 (USD Million)
Table 21 Autoimmune Disease Diagnostics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 22 North America: Autoimmune Disease Diagnostics Market Size, by Country, 2020–2029 (USD Million)
Table 23 North America: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 24 North America: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 25 North America: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 26 North America: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 27 U.S.: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 28 U.S.: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 29 U.S.: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 30 U.S.: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 31 Canada: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 32 Canada: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 33 Canada: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 34 Canada: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 35 Europe: Autoimmune Disease Diagnostics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 36 Europe: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 37 Europe: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 38 Europe: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 39 Europe: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 40 Germany: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 41 Germany: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 42 Germany: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 43 Germany: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 44 France: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 45 France: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 46 France: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 47 France: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 48 U.K.: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 49 U.K.: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 50 U.K.: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 51 U.K.: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 52 Italy: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 53 Italy: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 54 Italy: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 55 Italy: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 56 Spain: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 57 Spain: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 58 Spain: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 59 Spain: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 60 RoE: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 61 RoE: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 62 RoE: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 63 RoE: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 64 Asia-Pacific: Autoimmune Disease Diagnostics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 65 Asia-Pacific: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 66 Asia-Pacific: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 67 Asia-Pacific: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 68 Asia-Pacific: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 69 Japan: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 70 Japan: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 71 Japan: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 72 Japan: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 73 China: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 74 China: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 75 China: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 76 China: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 77 India: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 78 India: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 79 India: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 80 India: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 81 RoAPAC: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 82 RoAPAC: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 83 RoAPAC: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 84 RoAPAC: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 85 Latin America: Autoimmune Disease Diagnostics Market Size, by Country/Region, 2020–2029 (USD Million)
Table 86 Latin America: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 87 Latin America: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 88 Latin America: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 89 Latin America: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 90 Brazil: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 91 Brazil: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 92 Brazil: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 93 Brazil: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 94 Mexico: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 95 Mexico: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 96 Mexico: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 97 Mexico: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 98 RoLATAM: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 99 RoLATAM: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 100 RoLATAM: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 101 RoLATAM: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 102 Middle East & Africa: Autoimmune Disease Diagnostics Market Size, by Product Type, 2020–2029 (USD Million)
Table 103 Middle East & Africa: Autoimmune Disease Diagnostics Market Size, by Test Type, 2020–2029 (USD Million)
Table 104 Middle East & Africa: Autoimmune Disease Diagnostics Market Size, by Disease Type, 2020–2029 (USD Million)
Table 105 Middle East & Africa: Autoimmune Disease Diagnostics Market Size, by End User, 2020–2029 (USD Million)
Table 106 Recent Developments, by Company (2020–2022)
List of Figures
Figure 1 Research Process
Figure 2 Key Secondary Sources
Figure 3 Primary Research Techniques
Figure 4 Key Executives Interviewed
Figure 5 Breakdown of Primary Interviews (Supply-side & Demand-side)
Figure 6 Market Size Estimation
Figure 7 Autoimmune Disease Diagnostics Market Size, by Product Type, 2022 Vs. 2029 (USD Million)
Figure 8 Autoimmune Disease Diagnostics Market Size, by Test Type, 2022 Vs. 2029 (USD Million)
Figure 9 Autoimmune Disease Diagnostics Market Size, by Disease Type, 2022 Vs. 2029 (USD Million)
Figure 10 Autoimmune Disease Diagnostics Market Size, by End User, 2022 Vs. 2029 (USD Million)
Figure 11 Autoimmune Disease Diagnostics Market Size, by Geography
Figure 12 Market Dynamics
Figure 13 Autoimmune Disease Diagnostics Market Size, by Product Type, 2022–2029 (USD Million)
Figure 14 Autoimmune Disease Diagnostics Market Size, by Test Type, 2022–2029 (USD Million)
Figure 15 Autoimmune Disease Diagnostics Market Size, by Disease Type, 2022–2029 (USD Million)
Figure 16 Autoimmune Disease Diagnostics Market Size, by End User, 2022-2029 (USD Million)
Figure 17 Autoimmune Disease Diagnostics Market Size, by Geography, 2022–2029 (USD Million)
Figure 18 North America: Autoimmune Disease Diagnostics Market Snapshot
Figure 19 Europe: Autoimmune Disease Diagnostics Market Snapshot
Figure 20 Asia-Pacific: Autoimmune Disease Diagnostics Market Snapshot
Figure 21 Latin America: Autoimmune Disease Diagnostics Market Snapshot
Figure 22 Key Growth Strategies Adopted by Leading Players (2020–2022)
Figure 23 Autoimmune Disease Diagnostics Market: Competitive Benchmarking Based on Product Type
Figure 24 Autoimmune Disease Diagnostics Market: Competitive Benchmarking Based on Geography
Figure 25 Market Share Analysis: Autoimmune Disease Diagnostics Market (2021)
Figure 26 Thermo Fisher Scientific Inc.: Financial Overview (2021)
Figure 27 Bio-Rad Laboratories, Inc: Financial Overview (2021)
Figure 28 Danaher Corporation.: Financial Overview (2021)
Figure 29 Abbott Laboratories: Financial Overview (2021)
Figure 30 F. Hoffmann-La Roche AG: Financial Overview (2021)
Figure 31 Siemens Healthineers AG: Financial Overview (2021)
Figure 32 Grifols, S.A.: Financial Overview (2021)
Figure 33 Myriad Genetics, Inc.: Financial Overview (2021)
This report provides pre & post COVID-19 market estimates.
This report provides pre & post COVID-19 market estimates.
Published Date: May-2023
Published Date: Feb-2023
Published Date: Nov-2022
Published Date: May-2022
